Translations:SGLT2 inhibitor/11/en
In August 2018, the FDA issued a warning of an increased risk of Fournier gangrene in patients using SGLT2 inhibitors. The absolute risk is considered very low.
In August 2018, the FDA issued a warning of an increased risk of Fournier gangrene in patients using SGLT2 inhibitors. The absolute risk is considered very low.